Abstract
ObjectiveThe Systemic Lupus Erythematosus (SLE) Responder Index (SRI), developed as a primary outcome measure for use in clinical trials, captures improvement in SLE disease activity without concomitant worsening in disease...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have